Concepedia
Statistics
Publications
35
Citations
3.5K
H-Index
26
Active since
1990
Affiliations
GlaxoSmithKline (United Kingdom)(Current)
Eisai (United States)
Imperial College London
Eisai (United Kingdom)
GlaxoSmithKline (United States)
Robert Lai is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, alzheimer disease, and pharmacology.
Publications per year
1990–2022
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2021 · 817 citations · Full text
Medicine, Neurology, Pharmacology +17
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Claude M. Wischik, Patricia C. Edwards, Robert Lai et al. · Proceedings of the National Academy of Sciences · 1996 · 541 citations
Life Sciences, Neurobiology, Neuroscience +17
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
Veronika Logovinsky, Andrew Satlin, Robert Lai et al. · Alzheimer s Research & Therapy · 2016 · 283 citations · Full text
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans
Boris A. Chizh, M. O'Donnell, Antonella Napolitano et al. · Pain · 2007 · 249 citations
Medicine, Pharmacology, Pain Medicine +5
Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury
Praveen Anand, Ravikiran Shenoy, Joanne Palmer et al. · European Journal of Pain · 2011 · 170 citations
Medicine, Pharmacology, Pharmacotherapy +17
1–5 of 35